Study assesses outcomes of therapies with novel agents
Autologous anti-CD19 agent produces impressive survival improvements
Interim results of phase 2 trial are promising
Overly restrictive exclusions may lead to racial disparities and unrealistic outcomes
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study results from ASH 2019 shed light on treatment